Service Optimisation of AML Diagnostic Testing Pathway

This document is a report detailing a collaborative working project between Astellas Pharma Ltd, Bionical Solutions Ltd, and Addenbrookes Hospital focused on the service optimisation of the Acute Myeloid Leukaemia (AML) Diagnostic Testing Pathway. The objective is to conduct a service review of the AML Diagnostic Testing Pathway to enhance its efficiency and effectiveness in patient management. The report outlines the significance of genetic testing for AML gene mutations, emphasizing its critical role in informing treatment decisions and facilitating timely treatment initiation. It discusses the need for efficient referral and testing pathways, particularly for elderly patients, to improve patient outcomes. The project aims to identify inefficiencies, delays, and bottlenecks within the current pathway, ultimately leading to improved service delivery and patient experiences. Astellas is committed to supporting the NHS in this initiative, fostering partnerships to enhance care standards and patient well-being.